IMARC Group, a leading market research company, has recently released a report titled "Minimal Residual Disease (MRD) Testing Market by Technology (Flow Cytometry, Polymerase Chain Reaction (PCR), Next Generation Sequencing (NGS), and Others), Application (Hematological Malignancy, Solid Tumors), End User (Hospitals and Speciality Clinics, Diagnostic Laboratories, Academic and Research Institutes, and Others), and Region 2025-2033." The study provides a detailed analysis of the industry, including the global minimal residual disease (MRD) testing market size, share, trends, growth and forecast. The report also includes competitor and regional analysis and highlights the latest advancements in the market.
Market Overview
The global minimal residual disease (MRD) testing market was valued at USD 2.3 billion in 2024. It is projected to reach USD 5.5 billion by 2033, growing at a CAGR of 9.7% during the forecast period of 2025-2033. Market growth is fueled by advancements in healthcare, extensive RD, and the increasing adoption of sensitive diagnostic technologies such as flow cytometry, PCR, and next-generation sequencing. MRD testing is crucial for early detection of cancer recurrence and personalized treatment planning.
Study Assumption Years
- Base Year: 2024
- Historical Period: 2019-2024
- Forecast Period: 2025-2033
Minimal Residual Disease (MRD) Testing Market Key Takeaways
- Current Market Size: USD 2.3 Billion (2024)
- CAGR: 9.7%
- Forecast Period: 2025-2033
- MRD testing is used to detect residual cancer cells post-treatment in diseases such as leukemia, lymphoma, multiple myeloma, and some solid tumors.
- Polymerase chain reaction (PCR) holds the largest share among the technologies used in MRD testing.
- Hematological malignancies (leukemia and lymphoma) represent the largest application segment.
- Hospitals and specialty clinics are the leading end user segment in the MRD testing market.
- North America is the largest regional market driven by rising cancer prevalence, healthcare growth, and active RD.
Claim Your Free “Minimal Residual Disease (MRD) Testing Market” Insights Sample PDF: https://www.imarcgroup.com/minimal-residual-disease-testing-market/requestsample
Market Growth Factors
The rising incidence of cancer is expected to propel the global MRD testing market. This highly sensitive and specific test detects residual cancer at the molecular level and enables prompt treatment and targeted therapy. The market will also be driven by uptake of MRD testing in hematological cancers such as leukemia and lymphoma that originate in blood-forming and/or immune cells.
The increase in personalized medicine and the need for both consumers/patients and health care providers to use diagnostics to develop treatment plans and monitor results is another driver of the market. Artificial intelligence with MRD testing can help in diagnosis and risk stratification, recurrence pattern identification and provide clinicians the means to better manage patients.
The market is also driven by the increased adoption of next-generation sequencing (NGS) technology, which aids in genetic analysis by sequencing DNA or RNA to identify mutations and variants associated with cancer. In addition, increasing awareness regarding the presence of cancer-causing agents and their effects, and increasing investments and efforts in the medical industry are contributing to the growth of the MRD testing market.
Minimal Residual Disease (MRD) Testing Market Segmentation:
Technology Insights:
- Flow Cytometry
- Polymerase Chain Reaction (PCR)
- Next Generation Sequencing (NGS)
- Others
The technology segment includes diagnostic methods such as flow cytometry, PCR, NGS, and other techniques. PCR is the largest segment by market share.
Application Insights:
- Hematological Malignancy
- Leukemia
- Lymphoma
- Solid Tumors
Applications cover hematological malignancies, subdivided into leukemia and lymphoma, and solid tumors. Hematological malignancies hold the largest market share.
End User Insights:
- Hospitals and Specialty Clinics
- Diagnostic Laboratories
- Academic and Research Institutes
- Others
End users include hospitals and specialty clinics, diagnostic labs, academic and research institutes, and others. Hospitals and specialty clinics are the dominant segment.
Regional Insights:
- North America (United States, Canada)
- Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
- Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
- Latin America (Brazil, Mexico, Others)
- Middle East and Africa
North America leads the global MRD testing market, attributed to the high prevalence of cancer, robust healthcare infrastructure, and significant RD investments. The region includes key countries such as the United States and Canada and benefits from technological advancements and growing awareness about early cancer detection.
Key Players
- Adaptive Biotechnologies Corporation
- Arup Laboratories Inc.
- Bio-Rad Laboratories Inc.
- Guardant Health
- Invivoscribe Inc.
- Natera Inc.
- NeoGenomics Laboratories Inc.
- Sysmex Corporation
Ask Analyst For Request Customization: https://www.imarcgroup.com/request?type=reportid=7248flag=E
If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.
About Us
IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.
Contact Us
IMARC Group,
134 N 4th St. Brooklyn, NY 11249, USA,
Email: sales@imarcgroup.com,
Tel No: (D) +91 120 433 0800,
United States: +1-201971-6302
